Sarepta sells priority review voucher to Gilead for $125mm

Sarepta Therapeutics Inc. sold its rare pediatric disease priority review voucher (PRV) to Gilead Sciences Inc. for $125mm. Sarepta was granted the PRV when Exondys51 was approved by the FDA for patients with Duchenne muscular dystrophy amenable to exon skipping, and will now use the cash from the sale to support development of additional exon skipping candidates and enhancement of the company's antisense platform.